BSEInsider Trading / SAST1d ago · 24 Sept 2026, 06:52 pm

Closure of Trading Window

Shukra Pharmaceuticals Ltd · 524632

✦ AI Summary

Shukra Pharmaceuticals Ltd has announced the closure of its trading window for dealing in its securities from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ended September 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Shukra Pharmaceuticals Ltd - 524632 - Closure of Trading Window

Attachments (1)

📄

1d2b87f9-e8b1-4303-ae13-6f316e0b9657.pdf

pdf

Download →
View document text
SHUKRA PHARMACEUTICALS LTD. 24th September,2026 To, To, The Listing Compliance Department The Listing Department BSE Limitetl National Stock Exchange of India Limited P. J. Towers, Dalal Street Exchange Plaza, C-1, Block G Mumbai - 400001 Bandra Kurla Complex, Bandra (East) Scrip Code:524632 Mumbai - 40005f Symbol: SHUKRAPHAR Dear Sir/Madam, This is to inform you that the Company is closing its Trading window for dealing in the securities of the Company by the Promoters, members of the Promoter Group, Directors, KMPs, Insiders, Designated and Connected persons and their irnmediate relatives from Thursday, October 1,2026 till 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended September 30, 2026 pursuant to the provisions of the Clause 4(2) of Schedule B read with Regulation 9 of Securities and Exchange Board of India (Prolribition of lnsider Trading) Regulations, 2Ol5 (as amended from time to time) and SEgl Circular No. SEBI/HO/ISD/ISD-SEC -4 IP I CIR/2022/ IO7 dated August 5, 2022 and SEBI/I{O/ISD/ISD-PoD-2lPlCIPU2023ll24 dated July 19, 2023 read with Company's "Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by Designated Persor.rs" ("lnsider Trading Code"). Accordingly, all the Designated persons (including dependants and immediate relatives as per code) and cotlnected persons are advised not to enter into any transaction involving the securities of the Company dLrring the aforesaid period of closure of trading window. The date of the Board Meeting in connection with publishing its Unaudited Financial Results for the quarter ended September 30, 2026 will be announced in due course. You are requested to take the sarne on record. Thanking YoLr. Yours Faithfully, For Shukra Pharmaceuticals Shivkant Dhakad Company Secretary and M. No. A80894 CIN : I24231GJ1993P1C019079 Regd. Office : 3rd Floor; "VEER HOUSE" Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054. FactoryAdd. : 795, Rakanpu[ Sola-santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, lndia, Ph.:O2764-2863L7 Email : jnf"q.@.shu"kr"a"pha;m_q.pgulle_qls,-cQ.m website : www.shukrapharmaceuticals.com